-
Je něco špatně v tomto záznamu ?
Cerebrospinal fluid CXCL13 in non-borrelial central nervous system infections: contribution of CXCL13 to the differential diagnosis
D. Smíšková, O. Džupová, L. Moravcová, D. Pícha
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- Borrelia * MeSH
- chemokin CXCL13 mozkomíšní mok MeSH
- diferenciální diagnóza MeSH
- lidé MeSH
- lymská neuroborelióza * diagnóza mozkomíšní mok MeSH
- mozkomíšní mok MeSH
- prospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The chemokine CXCL13 in cerebrospinal fluid (CSF) is used as a diagnostic marker of Lyme neuroborreliosis (LNB). However, the elevated levels in other non-borrelial CNS infections and the lack of a clearly defined cut-off value are limitations of the test. METHODS: In our prospective study, we evaluated CSF CXCL13 levels in patients with LNB (47 patients), tick-borne encephalitis (TBE; 46 patients), enteroviral CNS infections (EV; 45 patients), herpetic CNS infections (HV; 23 patients), neurosyphilis (NS; 11 patients) and controls (46 patients). The correlation of CXCL13 with CSF mononuclears was determined in all groups. RESULTS: Median CXCL13 was significantly higher in LNB group; however, the cut-off value of 162 pg/mL was also exceeded in 22% of TBE patients, 2% EV patients, 44% HV patients and in 55% patients with NS. Sensitivity and specificity were 0.83 and 0.78, respectively, with a Youden index of 0.62. CXCL13 was significantly correlated with CSF mononuclears (p = .0024), but the type of infectious agent had a greater influence on CXCL13 levels. CONCLUSIONS: Increased CXCL13 levels are useful for LNB diagnostics, but other non-purulent CNS infections causes should be considered if intrathecal synthesis of borrelia specific antibodies is not confirmed or clinical manifestations are atypical.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010816
- 003
- CZ-PrNML
- 005
- 20230801132634.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/23744235.2023.2222178 $2 doi
- 035 __
- $a (PubMed)37317698
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Smíšková, Dita $u Department of Infectious Diseases, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic $1 https://orcid.org/0000000156996474 $7 xx0139471
- 245 10
- $a Cerebrospinal fluid CXCL13 in non-borrelial central nervous system infections: contribution of CXCL13 to the differential diagnosis / $c D. Smíšková, O. Džupová, L. Moravcová, D. Pícha
- 520 9_
- $a BACKGROUND: The chemokine CXCL13 in cerebrospinal fluid (CSF) is used as a diagnostic marker of Lyme neuroborreliosis (LNB). However, the elevated levels in other non-borrelial CNS infections and the lack of a clearly defined cut-off value are limitations of the test. METHODS: In our prospective study, we evaluated CSF CXCL13 levels in patients with LNB (47 patients), tick-borne encephalitis (TBE; 46 patients), enteroviral CNS infections (EV; 45 patients), herpetic CNS infections (HV; 23 patients), neurosyphilis (NS; 11 patients) and controls (46 patients). The correlation of CXCL13 with CSF mononuclears was determined in all groups. RESULTS: Median CXCL13 was significantly higher in LNB group; however, the cut-off value of 162 pg/mL was also exceeded in 22% of TBE patients, 2% EV patients, 44% HV patients and in 55% patients with NS. Sensitivity and specificity were 0.83 and 0.78, respectively, with a Youden index of 0.62. CXCL13 was significantly correlated with CSF mononuclears (p = .0024), but the type of infectious agent had a greater influence on CXCL13 levels. CONCLUSIONS: Increased CXCL13 levels are useful for LNB diagnostics, but other non-purulent CNS infections causes should be considered if intrathecal synthesis of borrelia specific antibodies is not confirmed or clinical manifestations are atypical.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Borrelia $7 D001898
- 650 _2
- $a chemokin CXCL13 $x mozkomíšní mok $7 D054382
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 12
- $a lymská neuroborelióza $x diagnóza $x mozkomíšní mok $7 D020852
- 650 _2
- $a mozkomíšní mok $7 D002555
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Džupová, Olga $u Department of Infectious Diseases, Third Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic
- 700 1_
- $a Moravcová, Lenka $u Department of Infectious Diseases, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic
- 700 1_
- $a Pícha, Dušan $u Department of Infectious Diseases, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic
- 773 0_
- $w MED00191578 $t Infectious diseases (London, England) $x 2374-4243 $g Roč. 55, č. 8 (2023), s. 551-558
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37317698 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132631 $b ABA008
- 999 __
- $a ok $b bmc $g 1963315 $s 1197081
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 55 $c 8 $d 551-558 $e 20230615 $i 2374-4243 $m Infectious diseases $n Infect Dis (Lond) $x MED00191578
- LZP __
- $a Pubmed-20230718